Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailEfficacy of the metaflumizone-amitraz association in a case of canine straelensiosis (Straelensia cynotis)
Franc, A.; Mignon, Bernard ULg

in Annales de Médecine Vétérinaire (2011), 155

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailEfficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Caron, Ph; Beckers, Albert ULg; Cullen, C. R. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(1), 99-104

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this ... [more ▼]

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 +/- 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 +/- 0.22 ng/ml) and IGF-I (317 +/- 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 +/- 0.19 ng/ml; IGF-I, 323 +/- 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during lanreotide Autogel treatment. In conclusion, this clinical study shows that lanreotide Autogel is at least as efficacious and well tolerated as lanreotide 30 mg. This new long-acting lanreotide formulation, lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailEfficacy of Trichoderma asperellum oil formulations on the control of Cocoa Black Pod Disease (Phytophthora megakarya)
Mbarga, J.B.; Martijn Ten Hoopen, G.; Begoude, A.D. et al

in Communications in Agricultural and Applied Biological Sciences (2012), 77(3), 65-74

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailThe Efficacy of Two Vaccination Schemes against Experimental Infection with a Virulent Amyxomatous or a Virulent Nodular Myxoma Virus Strain
Marlier, Didier ULg; Mainil, Jacques ULg; Boucraut-Baralon, C. et al

in Journal of Comparative Pathology (2000), 122(2-3, Feb-Apr), 115-22

Two types of myxomatosis vaccine are available commercially, namely, vaccine prepared from the Shope fibroma virus (SFV) and that prepared from an attenuated myxoma virus (MV) strain, e.gSG33. An ... [more ▼]

Two types of myxomatosis vaccine are available commercially, namely, vaccine prepared from the Shope fibroma virus (SFV) and that prepared from an attenuated myxoma virus (MV) strain, e.gSG33. An experiment was designed to compare two vaccination schemes for their ability to protect rabbits against challenge with either a virulent amyxomatous MV strain or a virulent nodular MV strain. Apart from a difference in the cutaneous expression of the disease, the two challenge strains resembled each other in respect of mortality rate, naso-conjunctival shedding of virus, and tissue infection. Vaccination with SFV alone failed to prevent clinical signs, naso-conjunctival shedding or tissue infection. Vaccination with SFV followed by a booster inoculation with SG33 protected rabbits against the development of clinical signs and significantly reduced both viral shedding in naso-conjunctival exudates and viral infection of eyelids, lungs and testes; virus was, however, isolated from testes of some surviving animals. [less ▲]

Detailed reference viewed: 28 (3 ULg)
Peer Reviewed
See detailEfficacy of upper urinary tract stones treatment by ESWL under local anesthesia, with the use of the Dornier Compact alpha Lithotriptor.
Leduc, frédéric; Ben Younes, Adelin; Andrianne, Robert ULg et al

Poster (2002, September)

Detailed reference viewed: 68 (5 ULg)
Peer Reviewed
See detailEfficience et bilan de l'azote apporté par l'engrais et par les eaux usées traitées.
Khelil, M. N.; Rejeb, S.; Destain, Jean-Pierre ULg et al

Conference (2003, September)

Detailed reference viewed: 27 (1 ULg)
Full Text
See detailEfficiency and competition in financial services
Fecher-Bourgeois, Fabienne ULg; Pestieau, Pierre ULg

E-print/Working paper (1992)

Detailed reference viewed: 8 (1 ULg)
See detailEfficiency and competition in financial services
Fecher-Bourgeois, Fabienne ULg; Pestieau, Pierre ULg

Report (1992)

This paper presents new estimates of technical efficiency and multi-factor productivity growth for the OECD financial services (banking and insurance) sector, over the period 1971-86. In addition, it ... [more ▼]

This paper presents new estimates of technical efficiency and multi-factor productivity growth for the OECD financial services (banking and insurance) sector, over the period 1971-86. In addition, it provides tests of two conjectures: can we talk of convergence in productivity growth across OECD members, particularly EC countries, and to what extent can prevailing competition explain variation in efficiency and productivity growth? [less ▲]

Detailed reference viewed: 20 (4 ULg)
See detailEfficiency and competition in OECD financial services
Fecher-Bourgeois, Fabienne ULg; Pestieau, Pierre ULg

in Fried, H.; Lovell, K.; Schmidt, S. (Eds.) The measurement of productive efficiency: techniques and applications (1993)

Detailed reference viewed: 84 (4 ULg)
See detailEfficiency and equity
Demeuse, Marc ULg; Crahay, Marcel ULg; Monseur, Christian ULg

in Hutmacher, W. (Ed.) In pursuit of equity in education : Using international indicators to compare policies (2001)

Detailed reference viewed: 31 (4 ULg)
Full Text
See detailEfficiency and institutional arrangements in the Belgian nursing home industry
Gathon, Henry-Jean ULg; Boveroux, Philippe; Debrule, Frédérique

E-print/Working paper (1995)

Detailed reference viewed: 13 (0 ULg)
See detailEfficiency and productivity of the health sector in the OECD countries (1970-1994)
Fecher-Bourgeois, Fabienne ULg

Scientific conference (1998, November)

Detailed reference viewed: 3 (0 ULg)
See detailEfficiency and productivity of the insurance industry
Fecher-Bourgeois, Fabienne ULg

Conference (1994, August)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailEfficiency and productivity of the insurance industry in the OECD countries
Fecher-Bourgeois, Fabienne ULg; Donni, Olivier

in Geneva Papers on Risk & Insurance - Issues & Practice (1997), 22(No. 85, October 1997), 523-535

Detailed reference viewed: 16 (5 ULg)